1- (4'- hydroxy- 2'- butenoxy)methyl- 2- nitroimidazole (RK 28)

08/01/1988 - "Therefore, RK-28 was effective in the treatment of the experimental pancreatic cancer (the enhancement ratio: 1.37). "
01/01/1992 - "To reduce its toxicity and increase its sensitizing activity, intratumoral injection of RK-28 was performed during intraoperative radiation therapy for pancreatic cancer. "

01/01/1992 - "Pharmacokinetic studies demonstrated several metabolites of RK-28 in both serum and tumor tissues. "
08/01/1988 - "When combined with 30 or 40 Gy of irradiation, which is applicable to intraoperative irradiation, RK-28 induced a longer period of tumor suppression and a higher tumor regression ratio than irradiation alone. "
08/01/1988 - "These results indicate that RK-28 significantly increases the effect of intraoperative irradiation and this combination therapy could possibly induce remarkable effect on tumor regression and long-term survival."
01/01/1992 - "After intratumoral injection, the tumor drug concentration ranged from 123 micrograms/g to 9,292 micrograms/g just after intraoperative radiation therapy (30-50 min after injection of the compound), while the serum concentration ranged from 4.1 to 9.8 micrograms/ml. The tumor drug concentration was 23.3 micrograms/g at 45 min after intravenous injection of RK-28. "
08/25/1985 - "[Radiosensitizing effect of new hypoxic cell radiosensitizer, RK-28 on experimental animal normal tissue and Ehrlich tumor]."